NASDAQ:ALMR Alamar Biosciences Q1 2026 Earnings Report $32.14 -1.08 (-3.25%) As of 09/23/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Alamar Biosciences EPS ResultsActual EPS-$1.74Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlamar Biosciences Revenue ResultsActual Revenue$26.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlamar Biosciences Announcement DetailsQuarterQ1 2026Date5/8/2026TimeBefore Market OpensConference Call DateFriday, May 8, 2026Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alamar Biosciences Earnings HeadlinesAlamar Biosciences, Inc. (ALMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comAlamar Biosciences, Inc. (NASDAQ:ALMR) Given Consensus Rating of "Hold" by AnalystsSeptember 14, 2026 | americanbankingnews.comI went to a party with Elon...Josh Baylin, a former Bloomberg tech reporter and ex-SAC Capital analyst, has spent weeks building a paper trail pointing to a new Elon-linked AI device. The FCC recently granted a key approval tied to the project, adding another data point to Baylin's research. His full report, along with the name and ticker of the stock he's watching, is available free.September 24 at 1:00 AM | Stansberry Research (Ad)Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 1, 2026 | globenewswire.comAlamar Biosciences Stock Price HistoryAugust 22, 2026 | investing.comAlamar Biosciences (ALMR) Q2 2026 Earnings Call TranscriptAugust 18, 2026 | finance.yahoo.comSee More Alamar Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alamar Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alamar Biosciences and other key companies, straight to your email. Email Address About Alamar BiosciencesAlamar Biosciences (NASDAQ:ALMR) is a life sciences company developing technologies for highly sensitive protein detection and analysis. Its products are designed to help researchers identify and measure low-abundance biomarkers associated with diseases, including cancer, neurodegenerative disorders and immune-related conditions. The company’s principal technology is the NULISA platform, which uses digital immunoassay methods to improve the sensitivity and multiplexing of protein biomarker analysis. Alamar offers NULISA-based products and workflows, including solutions for targeted protein panels and broader proteomic studies, as well as instrumentation and consumables intended for use by academic researchers, pharmaceutical companies and biotechnology organizations. Alamar Biosciences is headquartered in Fremont, California, and its research-use products support biomarker discovery and translational research. The company was founded by Yuling Luo, who has served as its chief executive officer and has led the development of its protein analysis technology.View Alamar Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
